Answers are grounded in this paper and cite their sources.
Variant filtration and prioritization were performed in Agilent Alissa Interpret and Geneyx using an epilepsy-focused strategy integrating population frequency (gnomAD), predicted functional impact, ACMG/ClinVar interpretation frameworks, inheritance modeling, and phenotype-driven ranking.Candidate variants underwent multidisciplinary review.Variants deemed clinically significant or strong research candidates were recommended for orthogonal confirmation and parental segregation analysis when available.Results: GS identified clinically relevant findings across variant types not previously detected by enrichment-based panels. SNVs/indels: 2 of 25 probands (8%) carried likely pathogenic or pathogenic SNVs consistent with the clinical epilepsy phenotype. Structural variants: 10 of 25 probands (40%) harbored candidate SVs, including intragenic deletions, duplications, and complex rearrangements that may disrupt epilepsy-associated genes. STR expansions: 3 of 25 probands (12%) demonstrated candidate repeat expansions in genes implicated in neurodevelopmental and epileptic phenotypes.Overall, 12 of 25 probands (48%) carried at least one candidate SV or STR expansion undetectable through prior panel testing.Confirmation and segregation analyses are ongoing, and several variants have been validated and are undergoing clinical interpretation. Conclusion:Comprehensive GS-based analysis markedly improves detection of clinically relevant variant classes, particularly SVs and STR expansions, in pediatric epilepsy patients with nondiagnostic prior testing.These data underscore substantial limitations of enrichment-based sequencing and highlight the need for genome-wide variant interrogation to close the diagnostic gap in pediatric epilepsy.The results support the integration of GS and advanced SV/STR pipelines as a first-tier diagnostic approach to improve molecular diagnosis and guide precision management for affected children, which aligns with the recommendation for a first-tier exome sequencing/genome sequencing test as outlined in the NSGC practice guidelines for unexplained epilepsies.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: